Brenig Therapeutics Raises $65 Million in Series A Financing

Brenig Therapeutics, a Dover, Delaware-based company focused on neurological drug development using an AI/ML-based discovery platform, has raised $65 million in a Series A financing round.

The round was led by NEA, with participation from OrbiMed, Torrey Pines Investments and BioGeneration Ventures. In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.

The company plans to use the funds to further develop BT-267 through studies in healthy volunteers and to conduct proof-of-concept studies in patients with idiopathic Parkinson’s disease.

Brenig is led by Iain Dukes MA DPhil, CEO and Chairman. The company is developing small molecule drugs using an AI/ML approach through a partnership with Expert Systems Inc., a drug accelerator that has generated multiple clinical candidates across multiple therapeutic areas.

BT-267 is a small molecule LRKK2 inhibitor with a PK profile that allows for high and sustained brain exposure and minimal peripheral exposure, maximizing efficacy while minimizing target and extra-tissue toxicity.

FinMKB

23/07/2024